Lexeo Therapeutics (NASDAQ:LXEO) Given New $23.00 Price Target at HC Wainwright

Lexeo Therapeutics (NASDAQ:LXEO) had its price target lifted by HC Wainwright from $21.00 to $23.00 in a research report report published on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts also recently issued reports on LXEO. Royal Bank of Canada restated an “outperform” rating and set a $24.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, August 13th. Leerink Partners cut their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Wednesday, November 13th. Finally, Chardan Capital lifted their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $22.71.

Lexeo Therapeutics Stock Performance

LXEO stock opened at $6.65 on Thursday. The company has a 50 day moving average price of $9.01 and a 200 day moving average price of $12.23. Lexeo Therapeutics has a fifty-two week low of $6.65 and a fifty-two week high of $22.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 9.38. The stock has a market capitalization of $219.92 million and a PE ratio of -2.10.

Insider Buying and Selling at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $8.10, for a total transaction of $40,500.00. Following the completion of the sale, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at approximately $977,629.50. This trade represents a 3.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 12,500 shares of company stock valued at $113,300 in the last three months. 4.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LXEO. BNP Paribas Financial Markets boosted its position in shares of Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after acquiring an additional 3,591 shares during the period. Values First Advisors Inc. bought a new stake in Lexeo Therapeutics in the 3rd quarter valued at about $67,000. American International Group Inc. bought a new stake in Lexeo Therapeutics in the 1st quarter valued at about $79,000. MetLife Investment Management LLC increased its holdings in shares of Lexeo Therapeutics by 121.5% during the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after purchasing an additional 7,803 shares during the period. Finally, Rhumbline Advisers increased its holdings in shares of Lexeo Therapeutics by 37.3% during the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after purchasing an additional 3,627 shares during the period. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.